Compare Intel Corp (INTC) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Moderna, Inc. — how do they compare? Intel Corp trades at $100.1 (market cap $492.85B), while Moderna, Inc. trades at $60.45 (market cap $24.18B). The key difference: Intel Corp is far larger — about 20.4× Moderna, Inc.'s market cap, and Intel Corp pays a 2.24% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| INTC | MRNA | |
|---|---|---|
Market Cap | $492.85B | $24.18B |
Volume | 43,552,012 | — |
Sector | Technology | Health |
52-Week High | $140.94 | $81.80 |
52-Week Low | $21.81 | $22.36 |
Enterprise Value | $513.66B | $20.33B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $97.52, down 4.06% today amid a $20 billion stock offering announcement. Despite recent earnings beats, the stock faces pressure from dilution concerns while showing strong revenue growth in data center and AI segments. Technical indicators are bullish on moving averages but neutral on oscillators, with key resistance at $100. Fundamentals reveal a mixed picture with negative net income margins but improving operational cash flow trends.
The outlook remains cautiously optimistic with a $116.67 analyst price target suggesting 20% upside, though execution risks in foundry losses and competitive pressures persist. Investors should weigh the growth potential in AI against near-term dilution and margin challenges.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
